<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">arthyper</journal-id><journal-title-group><journal-title xml:lang="ru">Артериальная гипертензия</journal-title><trans-title-group xml:lang="en"><trans-title>"Arterial’naya Gipertenziya" ("Arterial Hypertension")</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1607-419X</issn><issn pub-type="epub">2411-8524</issn><publisher><publisher-name>Antihypertensive League</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18705/1607-419X-2009-15-3-268-274</article-id><article-id custom-type="elpub" pub-id-type="custom">arthyper-1354</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>Показатели адгезионной дисфункции эндотелия и факторы иммунного воспаления у больных гипертонической болезнью в сочетании с ишемической бо-лезнью сердца: динамика на фоне терапии Крестором</article-title><trans-title-group xml:lang="en"><trans-title>Adhesion endothelial dysfunction and immune inflammatory factors in hypertensive patients with coronary heart disease: effects of rosuvastatin</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Красильникова</surname><given-names>Е. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Krasilnikova</surname><given-names>E. I.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Нифонтов</surname><given-names>Е. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Nifontov</surname><given-names>E.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сергеева</surname><given-names>Е. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Sergeeva</surname><given-names>E. G.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Антонова</surname><given-names>Т. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Antono-Va</surname><given-names>T. V.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Жлоба</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Zhloba</surname><given-names>A. A.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Галкина</surname><given-names>О. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Galkina</surname><given-names>O. V.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Романова</surname><given-names>М. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Romanova</surname><given-names>M. A.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ГОУ ВПО «Санкт-Петербургский Государственный медицинский университет имени академика И.П. Павлова Федерального агентства по здравоохранению и социальному развитию»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>St Petersburg Pavlov State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>28</day><month>06</month><year>2009</year></pub-date><volume>15</volume><issue>3</issue><fpage>268</fpage><lpage>274</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Красильникова Е.И., Нифонтов Е.М., Сергеева Е.Г., Антонова Т.В., Жлоба А.А., Галкина О.В., Романова М.А., 2009</copyright-statement><copyright-year>2009</copyright-year><copyright-holder xml:lang="ru">Красильникова Е.И., Нифонтов Е.М., Сергеева Е.Г., Антонова Т.В., Жлоба А.А., Галкина О.В., Романова М.А.</copyright-holder><copyright-holder xml:lang="en">Krasilnikova E.I., Nifontov E., Sergeeva E.G., Antono-Va T.V., Zhloba A.A., Galkina O.V., Romanova M.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://htn.almazovcentre.ru/jour/article/view/1354">https://htn.almazovcentre.ru/jour/article/view/1354</self-uri><abstract><p>В статье представлены современные взгляды патогенез атеросклероза, в том числе рассматривается роль молекулы адгезии сосудистого эндотелия 1 типа, гомоцистеина и асимметричного диметиларгинина как факторов риска развития эндотелиальной дисфункции, инициации и прогрессирования атеросклероза. Наряду с данными клинических многоцентровых исследований Розувастатина (Крестор, AstraZeneca, Великобритания), представлены результаты собственного изучения влияния Крестора на динамику иммунных факторов повреждения эндотелия у больных гипертонической болезнью в сочетании с ишемической болезнью сердца.</p></abstract><trans-abstract xml:lang="en"><p>Modern views on atherosclerosis pathogenesis are briefly summarized regarding the role of vascular cell adhesion molecule-1, homocysteine and asymmetric dimethylarginine as risk factors for endothelial dysfunction and atherosclerosis onset and progression. Rosuvastatin (Crestor, AstraZeneca, Great Britain) efficiency data according to multicenter clinical trials are presented as well as the results of the own study on Crestor impact on immunological factors of endothelial lesion in hypertensive patients with coronary heart disease.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>дисфункция эндотелия</kwd><kwd>молекула адгезии сосудистого эндотелия 1 типа</kwd><kwd>гомоцистеин</kwd><kwd>розувастатин</kwd></kwd-group><kwd-group xml:lang="en"><kwd>endothelial dysfunction</kwd><kwd>vascular cell adhesion molecule-1</kwd><kwd>homocysteine</kwd><kwd>rosuvastatin</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Deedwania P.C., Hunninghake D.B., Bays H.E. et al. Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome //Am. J. Cardiol. - 2005. - Vol. 95, № 3. - P. 360-366.</mixed-citation><mixed-citation xml:lang="en">Deedwania P.C., Hunninghake D.B., Bays H.E. et al. Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome //Am. J. Cardiol. - 2005. - Vol. 95, № 3. - P. 360-366.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru"></mixed-citation><mixed-citation xml:lang="en"></mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Nissen S.E., Nicholls S.J., Sipahi I. et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis. The ASTEROID trial // JAMA. - 2006. - Vol. 295. - P. 1556-1565.</mixed-citation><mixed-citation xml:lang="en">Nissen S.E., Nicholls S.J., Sipahi I. et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis. The ASTEROID trial // JAMA. - 2006. - Vol. 295. - P. 1556-1565.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru"></mixed-citation><mixed-citation xml:lang="en"></mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Shepherd J., Hunninghake D.B., Stein E.A. et al. Safety of rosuvastatin // Am. J. Cardiol. - 2004. - Vol. 94, № 7. - P. 882-888.</mixed-citation><mixed-citation xml:lang="en">Shepherd J., Hunninghake D.B., Stein E.A. et al. Safety of rosuvastatin // Am. J. Cardiol. - 2004. - Vol. 94, № 7. - P. 882-888.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru"></mixed-citation><mixed-citation xml:lang="en"></mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Cheung R.C., Morrell J.M., Kallend D. et al. Safety profile of rosuvastatin as used in general practice in England: interim results of a prescription-event monitoring study // Drug Safety. - 2004. - Vol. 27, № 12. - P. 365 [Abstract].</mixed-citation><mixed-citation xml:lang="en">Cheung R.C., Morrell J.M., Kallend D. et al. Safety profile of rosuvastatin as used in general practice in England: interim results of a prescription-event monitoring study // Drug Safety. - 2004. - Vol. 27, № 12. - P. 365 [Abstract].</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru"></mixed-citation><mixed-citation xml:lang="en"></mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Ridker P.M., Danielson E., Fonseca F.A. et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein // N. Engl. J. Med. - 2008. - Vol. 359, № 21. - P. 2195-2207.</mixed-citation><mixed-citation xml:lang="en">Ridker P.M., Danielson E., Fonseca F.A. et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein // N. Engl. J. Med. - 2008. - Vol. 359, № 21. - P. 2195-2207.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru"></mixed-citation><mixed-citation xml:lang="en"></mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Lentz S. R., Haynes W.G. Homocysteine: is it a clinically important cardiovascular risk factor? // Cleve Clin. J. Med. - 2004. - Vol. 71, № 9. - P. 729-734.</mixed-citation><mixed-citation xml:lang="en">Lentz S. R., Haynes W.G. Homocysteine: is it a clinically important cardiovascular risk factor? // Cleve Clin. J. Med. - 2004. - Vol. 71, № 9. - P. 729-734.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru"></mixed-citation><mixed-citation xml:lang="en"></mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Жлоба А.А. Асимметричный диметиларгинин в качестве медиатора и маркера развития эндотелиальной дисфункции // Артериальная гипертензия. - 2007. - Т. 13, № 2. - С. 119-127.</mixed-citation><mixed-citation xml:lang="en">Жлоба А.А. Асимметричный диметиларгинин в качестве медиатора и маркера развития эндотелиальной дисфункции // Артериальная гипертензия. - 2007. - Т. 13, № 2. - С. 119-127.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru"></mixed-citation><mixed-citation xml:lang="en"></mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Жлоба А.А., Блашко Э.Л. Дополнительное лабораторное обследование пациента при гипергомоцистеинемии. Материалы научно-практической конференции " Передовые медицинские технологии практическому здравоохранению", посвященной 50-летию городской клинической больницы №20 г. Санкт-Петербурга, 2008. - 48 с.</mixed-citation><mixed-citation xml:lang="en">Жлоба А.А., Блашко Э.Л. Дополнительное лабораторное обследование пациента при гипергомоцистеинемии. Материалы научно-практической конференции " Передовые медицинские технологии практическому здравоохранению", посвященной 50-летию городской клинической больницы №20 г. Санкт-Петербурга, 2008. - 48 с.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru"></mixed-citation><mixed-citation xml:lang="en"></mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Dayal S., Lentz S.R. ADMA and hyperhomocysteinemia // Vasc. Med. - 2005. - Vol. 10 (Suppl 1). - P. S27-S33.</mixed-citation><mixed-citation xml:lang="en">Dayal S., Lentz S.R. ADMA and hyperhomocysteinemia // Vasc. Med. - 2005. - Vol. 10 (Suppl 1). - P. S27-S33.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru"></mixed-citation><mixed-citation xml:lang="en"></mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Zhloba A.A., Blashko E.L. Liquid chromatographic determination of total homocysteine in blood plasma with photometric detection // J. Chromatography. - 2004. - Vol. 800. - P. 275-280.</mixed-citation><mixed-citation xml:lang="en">Zhloba A.A., Blashko E.L. Liquid chromatographic determination of total homocysteine in blood plasma with photometric detection // J. Chromatography. - 2004. - Vol. 800. - P. 275-280.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru"></mixed-citation><mixed-citation xml:lang="en"></mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Петрищев Н.Н., Васина Л.В., Власов Т.Д. и др. Типовые формы дисфункции эндотелия // Клин. лаб. консилиум. - 2007. - Т. 18. - С. 31-35.</mixed-citation><mixed-citation xml:lang="en">Петрищев Н.Н., Васина Л.В., Власов Т.Д. и др. Типовые формы дисфункции эндотелия // Клин. лаб. консилиум. - 2007. - Т. 18. - С. 31-35.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru"></mixed-citation><mixed-citation xml:lang="en"></mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Zohlnhufer D., Brand K., Schipek K. et al. Adhesion of Monocyte Very Late Antigen-4 to Endothelial Vascular Cell Adhesion Molecule-1 Induces Interleukin-1β-Dependent Expression of Interleukin-6 in Endothelial Cells // Arterioscler. Thromb. Vasc. Biol. - 2000. - Vol. 20. - P. 353.</mixed-citation><mixed-citation xml:lang="en">Zohlnhufer D., Brand K., Schipek K. et al. Adhesion of Monocyte Very Late Antigen-4 to Endothelial Vascular Cell Adhesion Molecule-1 Induces Interleukin-1β-Dependent Expression of Interleukin-6 in Endothelial Cells // Arterioscler. Thromb. Vasc. Biol. - 2000. - Vol. 20. - P. 353.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru"></mixed-citation><mixed-citation xml:lang="en"></mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Cybulsky M.I., Iiyama K., Li H. et al. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis // J. Clin. Invest. - 2001. - Vol. 107, № 10. - P. 1209-1210.</mixed-citation><mixed-citation xml:lang="en">Cybulsky M.I., Iiyama K., Li H. et al. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis // J. Clin. Invest. - 2001. - Vol. 107, № 10. - P. 1209-1210.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru"></mixed-citation><mixed-citation xml:lang="en"></mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Dansky H.M., Barlow C.B., Lominska C. et al. Adhesion of monocytes to arterial endothelium and initiation of atherosclerosis are critically dependent on vascular cell adhesion molecule-1 gene dosage // Arterioscler. Thromb. Vasc. Biol. - 2001. - Vol. 21, № 10. - P. 1662-1667.</mixed-citation><mixed-citation xml:lang="en">Dansky H.M., Barlow C.B., Lominska C. et al. Adhesion of monocytes to arterial endothelium and initiation of atherosclerosis are critically dependent on vascular cell adhesion molecule-1 gene dosage // Arterioscler. Thromb. Vasc. Biol. - 2001. - Vol. 21, № 10. - P. 1662-1667.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru"></mixed-citation><mixed-citation xml:lang="en"></mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Ley K., Huo Y. VCAM-1 is critical in atherosclerosis // J. Clin. Invest. - 2001. - Vol. 107, № 10. - P. 1209-1210.</mixed-citation><mixed-citation xml:lang="en">Ley K., Huo Y. VCAM-1 is critical in atherosclerosis // J. Clin. Invest. - 2001. - Vol. 107, № 10. - P. 1209-1210.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru"></mixed-citation><mixed-citation xml:lang="en"></mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Huo Y., Hafezi-Moghadam A., Ley K. Role of vascular cell adhesion molecule-1 and fibronectin connecting segment-1 in monocyte rolling and adhesion on early atherosclerotic lesions // Circ. Res. - 2000. - Vol. 87. - P. 153-159.</mixed-citation><mixed-citation xml:lang="en">Huo Y., Hafezi-Moghadam A., Ley K. Role of vascular cell adhesion molecule-1 and fibronectin connecting segment-1 in monocyte rolling and adhesion on early atherosclerotic lesions // Circ. Res. - 2000. - Vol. 87. - P. 153-159.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru"></mixed-citation><mixed-citation xml:lang="en"></mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Lutters B., Leeuwenburgh M., Appeldoorn C. et al. Blocking endothelial adhesion molecules: a potential therapeutic strategy to combat atherogenesis // Curr. Opin. Lipidology. - 2004. - Vol. 15, № 5. - P. 545-552.</mixed-citation><mixed-citation xml:lang="en">Lutters B., Leeuwenburgh M., Appeldoorn C. et al. Blocking endothelial adhesion molecules: a potential therapeutic strategy to combat atherogenesis // Curr. Opin. Lipidology. - 2004. - Vol. 15, № 5. - P. 545-552.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru"></mixed-citation><mixed-citation xml:lang="en"></mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Gabor D. The levels of soluble adhesion molecules in diabetic and nondiabetic patients with combined hyperlipoproteinemia and the effect of ciprofibrate therapy // Angiology. - 2004. - Vol. 55, № 6. - P. 629-639.</mixed-citation><mixed-citation xml:lang="en">Gabor D. The levels of soluble adhesion molecules in diabetic and nondiabetic patients with combined hyperlipoproteinemia and the effect of ciprofibrate therapy // Angiology. - 2004. - Vol. 55, № 6. - P. 629-639.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru"></mixed-citation><mixed-citation xml:lang="en"></mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Otsuki M., Hashimoto K., Morimoto Y. et al. Circulating vascular cell adhesion molecule-1 (VCAM-1) in atherosclerotic NIDDM patients // Diabetes. - 1997. - Vol. 46, № 12. - P. 2096-2101.</mixed-citation><mixed-citation xml:lang="en">Otsuki M., Hashimoto K., Morimoto Y. et al. Circulating vascular cell adhesion molecule-1 (VCAM-1) in atherosclerotic NIDDM patients // Diabetes. - 1997. - Vol. 46, № 12. - P. 2096-2101.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru"></mixed-citation><mixed-citation xml:lang="en"></mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Wu J.T., Wu L.L. Association of Soluble Markers with Various Stages and Major Events of Atherosclerosis // Ann. Clin. Labor. Science. - 2005. - Vol. 35. - P. 240-250.</mixed-citation><mixed-citation xml:lang="en">Wu J.T., Wu L.L. Association of Soluble Markers with Various Stages and Major Events of Atherosclerosis // Ann. Clin. Labor. Science. - 2005. - Vol. 35. - P. 240-250.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru"></mixed-citation><mixed-citation xml:lang="en"></mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Vadas M.A, Gamble J.R. Endothelial adhesion molecules in atherogenesis. A concerto or a solo? // Circ. Res. - 1996. - Vol. 79, № 6. - P. 1216-1217.</mixed-citation><mixed-citation xml:lang="en">Vadas M.A, Gamble J.R. Endothelial adhesion molecules in atherogenesis. A concerto or a solo? // Circ. Res. - 1996. - Vol. 79, № 6. - P. 1216-1217.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru"></mixed-citation><mixed-citation xml:lang="en"></mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
